VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > 🌟 Greetings from the ESC Congress in London! 🇬🇧

<< Previous

Bullboard Posts

Next >>

Comment by jopatcloon Aug 31, 2024 10:34am

54 Views

Post# 36203933

RE:RE:🌟 Greetings from the ESC Congress in London! 🇬🇧

jopatclo wrote: GranhamB the manipulative vulture who sold the shares of his family and friends at the end of 2020 at a loss sold it at .07 or .08? and now since this time want to buy at a low price. sad manipulative broker guy. GrahamB do you want me to deliver your message or do you say you want to buy at .12?
GrahamB wrote:And yet after all these years. I have been correct- no sales, no China, no GE, no buyout, continued dilution, operating losses, and more promises and stories of waiting, waiting, wairing
Fake GranhamB the manipulator here are the real facts

GranhamBWalk,see before FDA V4.0 and Sales !now 1. The VMS+3.0 is our base version which we have been providing to major hospitals in Canada, Europe and USA and we will continue to provide it as a base model.

Dario Freitas likes this,Join us at ESC2024 for 3D echo w...

Interesting see = with all existing ultrasound machines post Dear Friend; in point 3. = c. (c. instantaneous calibration with all existing ultrasound machines, which makes the user experience seamless with the normal cardiac imaging procedure;) Dear Friend;

Attached is today’s news release announcing the approval for sale of the latest VMS+ model. Here is some background:

1. The VMS+3.0 is our base version which we have been providing to major hospitals in Canada, Europe and USA and we will continue to provide it as a base model.

2. The VMS+4.0 will be a premium model sold at a premium price, as it does so much more.

3. The more is:

a. broader applicability to all cardiac patients, even those with pacemakers and defibrillators who cannot go into an MRI and so the ability of clinicians to properly assess their hearts has been limited. This is an engineering breakthrough as up to now, the use of the VMS+ in such patients has been a restriction on its use - not any more;

b. automated analysis, which speeds up the analysis process and also provides even more reliability by eliminating operator-operator variability;

c. instantaneous calibration with all existing ultrasound machines, which makes the user experience seamless with the normal cardiac imaging procedure;

d. better 3D visualization of the whole beating heart, which allows the cardiologist to explain to patients exactly how the heart is misfiring and how it can be treated;

e. new detailed measurements of heart function, which allows the clinician to focus in on one chamber of the heart or even one area of the heart and measure its movement and ability to contract.

4. The Company has applied to US-FDA for clearance of the VMS+4.0 in the USA and we a finalizing an application for CE Mark for European approval.

5. The Company will now offer upgrades to its existing customers in Canada as well as marketing it to new hospitals and imaging centers.

Thank you for your interest and support as we continue to improve cardiac diagnostics for everyone, everywhere, and especially for children born with a heart defect.

Regards,

Dr. George Adams ICD.D